Clinical Core

临床核心

• 批准号: 10661526
• 负责人: SUMAN JAYADEV
• 金额: $ 109.14万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10661526
• 关键词: Abbreviations; Address; Adult; Affect; Age; Alaska Native; Algorithms; Alzheimer' s Disease; Alzheimer' s disease related dementia; American Indians; Anatomy; Automobile Driving; Autopsy; Biodiversity; Biological; Biological Markers; Biology; Blood; Brain; Calibration; Cerebrospinal Fluid; Cerebrovascular Disorders; Clinical; Clinical Data; Clinical Protocols; Cognitive; Cohort Studies; Collaborations; Communities; Consensus; Data; Data Set; Dementia; Detection; Disease; Education; Enrollment; Equitable healthcare; Evaluation; Faculty; Frontotemporal Dementia; Genetic; Genetic Risk; Genomics; Health; Heterogeneity; Human Genetics; Image; Imaging technology; Institution; Investigation; Justice; Knowledge; Liquid substance; Longitudinal cohort; Measures; Medical center; Memory; Methods; Modernization; Nerve Degeneration; Neuropsychological Tests; Neuropsychology; Participant; Pathologic; Pathology; Pattern; Persons; Phenotype; Population; Process; Protocols documentation; Psychometrics; Quality Control; Race; Research; Research Personnel; Resistance; Resources; Risk; Science; Skin; Standardization; Testing; Underrepresented Populations; Universities; Variant; Washington; Wellness Center; Work; adjudication; biological heterogeneity; clinical center; cognitive enhancement; cohort; community based participatory research; comorbidity; data management; demographics; diagnostic algorithm; disease heterogeneity; education research; effective intervention; genome wide association study; improved; innovation; interoperability; mild cognitive impairment; multimodal neuroimaging; multimodality; neuropathology; normal aging; outreach; pathological aging; programs; prospective; recruit; research clinical testing; resilience; rural Americans; socioeconomics; statistics; translational study

Abstract The University of Washington (UW) Alzheimer Disease Research Center (ADRC) Clinical Core is a valuable component the center's overall aim of supporting meaningful and innovative ADRD research. Advances in human genetics, pathological and imaging technologies have revealed the biological diversity of ADRD. The UW Clinical Core aims to capture this spectrum of ADRD heterogeneity in its longitudinal cohort to support multi-modal study of participants. Sensitive phenotyping is critical to the interpretation of post-mortem pathology and ante-mortem imaging heterogeneity. To that end, we have expanded our neuropsychological evaluation to identify relative vulnerable and resilient cognitive domains. Acknowledging that effective ADRD therapies for all requires improving study of ADRD in under-represented groups, we have developed a strategy with our Outreach Recruitment and Engagement Core to enhance the diversity of our ADRC. Over the last 5 years the UW ADRC has built a strong collaborative relationship with the Partners for Native Health, led by Dr. Dedra Buchwald. In this cycle we continue this effort through developing consensus algorithms for longitudinal cognitive and clinical data collected by Dr. Buchwald's team. Additionally, we work with the UW ADRC's Native Research and Resource Core (NRRC) to build upon data derived from community based participatory research approaches in the AI/AN population and develop community sensitive uniform ADRD clinical evaluations. The rationale driving the Clinical Core composition is to a) reflect the UW ADRC scientific theme of heterogeneity and resilience b) respond to the scientific needs of the ADRC research community and c) increase the racial, socioeconomic and educational attainment diversity of the Clinical Core. In this cycle, the Clinical Core will 1) Characterize clinically and follow longitudinally persons with normal aging, prodromal and symptomatic ADRD representing the clinical, anatomic and risk heterogeneity of disease, and promote their inclusion into research 2) Promote the inclusion of underrepresented groups in ADRD research and collaborate to establish diagnostic algorithms in AI/AN studies 3) Use modern psychometric approaches to co-calibrate cognitive scores across UDS, pre-enrollment clinical tests, and external studies to integrate pre-enrollment cognitive data and facilitate interoperability across and 4) obtain longitudinal CSF, blood and skin biospecimens from a well-characterized cohort of research participants presenting with normal and pathological aging, prodromal dementia and ADRD.

抽象的 华盛顿大学（UW）阿尔茨海默氏病研究中心（ADRC）临床核心是有价值的 该中心的总体目的是支持有意义的创新性ADRD研究。进步 人类遗传学，病理和成像技术揭示了ADRD的生物学多样性。这 UW临床核心旨在在其纵向队列中捕获这种ADRD异质性的范围 参与者的多模式研究。敏感的表型对于验尸的解释至关重要 病理和验尸成像异质性。为此，我们扩大了神经心理学 评估以识别相对脆弱和弹性的认知领域。承认有效的adrd 所有人的疗法都需要改进对代表性不足的群体中ADRD的研究，我们已经制定了一种策略 我们的外展招聘和参与核心，以增强我们的ADRC的多样性。在过去的5个 多年来，UW ADRC与博士领导的原生卫生合作伙伴建立了牢固的合作关系。 Dedra Buchwald。在这个周期中，我们通过为纵向开发共识算法而继续进行这项努力 布赫瓦尔德博士团队收集的认知和临床数据。此外，我们与UW ADRC合作 本地研究和资源核心（NRRC）以基于社区的参与性的数据为基础 AI/A人群的研究方法并发展了社区敏感的统一ADRD临床 评估。驱动临床核心组成的理由是a）反映UW ADRC科学主题 异质性和弹性b）响应ADRC研究界的科学需求和C） 增加临床核心的种族，社会经济和教育成就多样性。在这个周期中， 临床核心将1）在临床上表征并跟随正常衰老，前驱和 有症状的ADRD代表疾病的临床，解剖和风险异质性，并促进其 纳入研究2）促进在ADRD研究中纳入代表性不足的群体并合作 在AI/A AN研究中建立诊断算法3）使用现代心理测量方法进行共校准 跨UDS的认知评分，注册前临床测试和外部研究，以整合预注册 认知数据并促进跨互操作性和4）获得纵向CSF，血液和皮肤 来自特征良好的研究参与者的生物测量，呈现正常和 病理衰老，前驱痴呆和ADRD。